Eye serums sold as cosmetics — not drugs — are regulated under different frameworks in the US and EU, and both have tightened their requirements in recent years. Understanding both is essential if you plan to sell internationally.
In the United States, topical eye serums are regulated by the FDA as cosmetics under the Federal Food, Drug, and Cosmetic Act. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) significantly updated US cosmetic compliance requirements. Key obligations now include: facility registration for manufacturers and packers (due annually), product listing with the FDA (required for products marketed in the US), good manufacturing practice compliance (FDA is developing formal GMP regulations), serious adverse event reporting to the FDA within 15 days, and safety substantiation — you must be able to demonstrate that your product is safe for its intended use, which in practice means you need stability data, a challenge test, and ideally a dermatologist or ophthalmologist safety review for a product used near the eye.
Claims matter enormously in the US. If you claim the serum "treats" dark circles, reduces puffiness caused by a medical condition, or otherwise crosses into drug territory, FDA may classify it as an over-the-counter drug — triggering a far more burdensome approval pathway. Stick to cosmetic claim language: "visibly brightens," "reduces the appearance of dark circles," "supports a more rested look."
Transexamic acid is not currently restricted under US FDA cosmetic regulations — it is permitted in cosmetics as a skin-conditioning agent. Verify the current status with your cosmetic chemist as regulatory landscapes evolve.
In the European Union, cosmetics are governed by EC Regulation No 1223/2009. Requirements include: a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor before market entry, product information file (PIF) maintained for 10 years, notification via the CPNP (Cosmetics Products Notification Portal) before placing on the market, responsible person designation (a legal EU entity), and ingredient restrictions per Annex II, III, IV, V, and VI of the regulation. TXA is not listed as a restricted ingredient under current EU annexes, but it is your safety assessor's responsibility to confirm safe use levels for periorbital application.
For both markets, ensure your INCI labeling is correct and complete. All ingredients must be listed on the label in descending order of concentration, using INCI nomenclature. For a 10 mL or 15 mL eye serum, label real estate is tight — work with a regulatory consultant early to ensure compliance without sacrificing design.
AJ Cosmo Labs connects founders with manufacturers who are experienced in both MoCRA compliance and EU dossier preparation, so you can vet partners on regulatory capability, not just fill capacity.
Read the full guide on Private Label Tranexamic Acid Niacinamide Eye Serum →